Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2018, Article ID 1215868, 9 pages
https://doi.org/10.1155/2018/1215868
Review Article

Application of Novel Drugs for Corneal Cell Regeneration

1Department of Ophthalmology, Kangwon National University Hospital, Kangwon National University, Chuncheon, Republic of Korea
2Singapore National Eye Centre, Singapore
3Singapore Eye Research Institute, Singapore
4Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
5Department of Ophthalmology, Faculty of Medicine, University Hospital “Jose E. Gonzalez”, Autonomous University of Nuevo Leon, Monterrey, NL, Mexico

Correspondence should be addressed to Jodhbir S. Mehta; moc.liamg@athemdoj

Received 27 December 2017; Revised 26 February 2018; Accepted 27 March 2018; Published 2 May 2018

Academic Editor: Enrique Mencía-Gutiérrez

Copyright © 2018 Sang Beom Han et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Corneal transplantation has been the only treatment method for corneal blindness, which is the major cause of reversible blindness. However, despite the advancement of surgical techniques for corneal transplantation, demand for the surgery can never be met due to a global shortage of donor cornea. The development of bioengineering and pharmaceutical technology provided us with novel drugs and biomaterials that can be used for innovative treatment methods for corneal diseases. In this review, the authors will discuss the efficacy and safety of pharmacologic therapies, such as Rho-kinase (ROCK) inhibitors, blood-derived products, growth factors, and regenerating agent on corneal cell regeneration. The promising results of these agents suggest that these can be viable options for corneal reconstruction and visual rehabilitation.

1. Introduction

Corneal blindness is one of the leading causes of reversible blindness worldwide [1]. Corneal transplantation has been the only method for the treatment of corneal blindness, of which penetrating keratoplasty has long been the major surgical procedure. More recently, partial thickness corneal transplantation, such as Descemet’s stripping endothelial keratoplasty (DSEK), Descemet’s membrane endothelial keratoplasty (DMEK), and deep anterior lamellar keratoplasty (DALK), has been gaining popularity due to better visual prognosis and reduced risk of rejection. However, a global shortage of donor corneal tissue makes it impossible to meet the demands for corneal transplantation with current cornea donation programs. In addition, despite the advancement of surgical techniques and devices, corneal transplantation is still associated with limitations, such as graft failure or rejection, difficulty of the surgical procedure, and complications including secondary glaucoma [2, 3].

Remarkable developments of novel biomaterials and stem cell-based tissue cultivation and expansion techniques during the past few decades might enable the mass production of synthetic corneal tissue and are expected to provide innovative treatment methods for corneal disease. Medical treatment using drugs, such as Rho-kinase (ROCK) inhibitors, blood-derived products, growth factors, and regenerating agent eye drops (RGTA), is also anticipated to have therapeutic potential. In this review, we aimed to provide information on the pharmacologic therapies for corneal cell regeneration using these drugs.

2. Rock Inhibitors

ROCK is a serine/threonine protein kinase that is activated by Rho and forms Rho/ROCK complex that regulates a variety of cellular functions, such as cell proliferation, differentiation, migration, contraction, and apoptosis [4, 5]. Therefore, the ROCK signaling pathway has drawn interest as a potential target for the treatment of diseases of multiple organs [4, 5]. Recent studies showed that the ROCK inhibitor might be an innovative therapeutic agent for various ocular diseases, particular for corneal endothelial decompensation [4]. Although corneal transplantation has been the only therapy for corneal endothelial dysfunction, studies indicate the potential of ROCK inhibitors as a less-invasive alternative to graft surgery [3].

2.1. ROCK Inhibitor for Corneal Endothelial Cell (CEC) Generation

Okumura et al. [6] demonstrated that a selective ROCK inhibitor, Y-27632, promoted CEC proliferation and adhesion and suppressed its apoptosis, indicating that the topical ROCK inhibitor has been therapeutic for CEC regeneration [6]. An experimental study showed that a ROCK inhibitor facilitated the proliferation of CECs by the modulation of cyclin and p27; both are regulators of the G1/S transition [7]. Peh et al. [8] also revealed that Y-27632 increased cell proliferation. In their study, the effect of the ROCK inhibitor on the proliferation of CEC was significant only in the corneas from younger donors, suggesting that CECs from older corneas might lose the proliferation potential that could be activated by the ROCK inhibitor [8]. The findings of another study that Y-27632 had no effect on the proliferation of human CECs, although it facilitated corneal endothelial wound healing ex vivo and in vitro, support the assumption [9].

ROCK inhibitor eye drops enhanced corneal endothelial wound healing in a rabbit CEC injury model [6, 7, 10]. Topical ROCK inhibitor instillation also led to the facilitation of corneal endothelial wound healing and the recovery of corneal transparency in a primate CEC damage model [11]. Y-27632 was also shown to enhance the proliferation and adhesion and suppress the apoptosis of primate CECs cultured in vitro [6, 12]. Considering that primate CECs also have limited proliferative capacity, these results suggest that the ROCK inhibitor may have a therapeutic effect on human corneal endothelial dysfunction.

Okumura et al. [13] postulated that topical application of the ROCK inhibitor could facilitate the proliferation and migration of the residual CECs after acute corneal endothelial damage, thereby decreasing the risk of corneal endothelial decompensation [13]. A preliminary study showed that topical administration of the ROCK inhibitor resulted in the recovery of corneal transparency in 1-2 months in all 3 patients with postoperative acute corneal endothelial decompensation [3].

The ROCK inhibitor could be an alternative to corneal transplantation for Fuchs’ endothelial corneal dystrophy (FECD). A human pilot study demonstrated that treatment with Y-27632 eye drops for patients with FECD resulted in the decrease in central corneal thickness and the recovery of corneal transparency in patients with corneal edema confined to the center, whereas the effect was not evident in those with diffuse corneal edema [3, 11, 14]. A recent case series study also revealed that descemetorhexis without graft surgery followed by topical ROCK inhibitor administration resulted in the restoration of corneal clarity and visual rehabilitation in patients with FECD [15].

2.2. ROCK Inhibitor for Tissue Engineering

For the treatment of corneal endothelial decompensation, the following two strategies for tissue engineering appears to be promising [1]: transplantation of bioengineered corneal endothelial cell sheet and [2] direct injection of cultivated CEC suspension to the anterior chamber [3].

Experimental studies showed that the transplantation of cultivated CECs on a collagen sheet can result in the restoration of corneal transparency and reduction of corneal edema [16, 17]. However, manipulation of the fragile monolayer sheet in the anterior chamber is technically challenging and is associated with the risk of CEC loss [3].

Theoretically, direct injection of CECs into the anterior chamber might be simple and less invasive compared to CEC sheet transplantation. In addition, the preparation of cells for transplantation may be easier, without the need for an artificial substrate [3]. The risk of CEC damage during the procedure might also be reduced. As the CECs injected into the anterior chamber may not spontaneously attach to Descemet’s membrane, methods for improving the adhesion of the injected CECs have been attempted, such as magnetic guidance of iron powder or superparamagnetic microspheres incorporated in the CECs [1820].

Considering that the ROCK inhibitor was proven to promote CEC adhesion onto a substrate [12], it may be postulated that the ROCK inhibitor can be helpful for promoting the attachment of CECs injected into the anterior chamber. An experimental study using a rabbit corneal endothelial dysfunction model demonstrated that intracameral injection of rabbit CECs combined with Y-27632, followed by keeping each rabbit in the facedown position for 3 hr, achieved enhanced attachment of donor cells onto host Descemet’s membrane and the restoration of corneal transparency [21], whereas CEC injection without the inclusion of Y-27632 led to persistent corneal edema [21].

Y-27632 also promoted the adhesion of intracamerally injected CECs onto Descemet’s membrane in both rabbit and primate corneal endothelial decompensation models and upregulated the expression of functional proteins including Na+/K+ ATPase and ZO-1, thereby leading to the resolution of corneal edema [22]. Another study revealed that intracameral injection of either human or monkey CECs in combination with Y-27632 led to the regeneration of monkey corneal endothelium, suggesting that intracameral injection of cultivated human CECs combined with the ROCK inhibitor may be a plausible therapeutic option for corneal endothelial diseases [2]. Preliminary data from a human clinical study showed that cultured human CECs injected in conjunction with ROCK achieved improvement of corneal edema and visual acuity without any serious adverse effect [3]. Although the results appear to be promising, further prospective randomized studies with a long-term follow-up are necessary to evaluate the efficacy and safety of ROCK inhibitors for the treatment of corneal endothelial diseases [3].

2.3. Other Effects of ROCK Inhibitor on Corneal Regeneration

The ROCK inhibitor was suggested to have additional effects that can be potentially applicable for corneal regeneration. Y-27632 was shown to promote both ex vivo and in vitro proliferation of limbal epithelial cell proliferation, suggesting it can be useful for the treatment of limbal stem cell deficiency [23]. Zhou et al. [24] also demonstrated that Y-27632 enhanced the cloning efficiency of limbal stem/progenitor cells by promoting their adhesion and capacity of reactive oxygen species scavenging in a rabbit model [24]. Y-27632 inhibited the transition of rabbit keratocyte to myofibroblast and modulated a wound healing process after a superficial lamellar keratectomy in a rabbit cornea [25]. Animal experimental studies revealed that ROCK inhibitors, fasudil and AMA0526, inhibited corneal neovascularization and opacity and facilitated corneal epithelial regeneration after corneal alkali burn [26, 27].

3. Blood-Derived Products

Application of blood-derived products for ocular surface diseases was first introduced in 1975 for 6 patients with chemical burns [28]. Since Tsubota et al. [29, 30] proved the efficacy and safety of autologous serum eye drops (ASE) for the treatment of dry eye disease (DED) and persistent epithelial defect (PED) [29, 30], studies have proven that blood-derived products are innovative therapeutic agents for various ocular surface disorders, such as DED [31], PED [32], neurotrophic keratitis [33], recurrent corneal erosion [34], and chemical burns [35].

3.1. Autologous Serum Eye Drops (ASE) [36]

ASE has a similar biochemical composition as human tears [37] and includes growth factors including epidermal growth factor (EGF) and transforming growth factor- (TGF-) β [38], chemokines, fibronectin, and various nutrients [38].

Consensus for the preparation method has never been established yet [37]. An in vitro experimental study indicated that an increased clotting time of 120 min or longer, a sharp centrifugation (3000 for 15 min), and dilution with balanced salt solution at 12.5–25% were optimal for corneal epithelial healing [39]. Clinically, 20% ASE is most frequently used to match the TGF-β concentration, which is 5 times higher in serum than in tears, to prevent delayed wound healing and promotion of corneal haze caused by TGF-β [30]. However, higher concentrations of ASE (50 to 100%) were also suggested to be effective and safe [40, 41]. A randomized prospective study showed that 100% ASE was more effective for the treatment of PED, Sjögren’s syndrome (SS), and non-Sjögren DED than 50% ASE [42].

Randomized clinical studies revealed that ASE was more effective than conventional treatment for the improvement of both symptoms and signs of DED [4345]. Kojima et al. [46] demonstrated that ASE suppressed apoptosis in the ocular surface epithelium and albumin contained in ASE recovered ocular surface damage [46]. ASE was superior to artificial tear in the improvement of dry eye signs after refractive surgery [47]. In addition, ASE can be a therapeutic option for PED refractory to conventional treatment [40, 48]. Schrader et al. [49] suggested that ASE combined with silicone hydrogel contact lenses might be helpful in recalcitrant PED [49]. Moreover, ASE was shown to be effective in facilitating reepithelialization of corneal graft after penetrating keratoplasty [50]. It also promoted corneal epithelial healing in patients with neurotrophic keratitis and aniridic keratopathy [51, 52]. A prospective study with a long-term follow-up revealed that ASE was effective for the prevention of recurrence in patients with recurrent corneal erosion [53]. However, a review of five randomized clinical trials that compared AS versus artificial tears or saline in DED patients revealed that no evidence of a benefit was found after two weeks of treatment, although there might be some short-term effect on symptoms with AS compared with artificial tears [54]. Therefore, we also believe further well-designed, large-scale randomized controlled studies are warranted to evaluate the efficacy of AS [54]. The absence of preservatives and high nutrient level in ASE increases the risk of sample contamination [55, 56]. Therefore, attention should be paid for the signs of infection in patients using ASE [36]. Lagnado et al. [55] recommended that sample vials should be stored frozen at −20°C for up to 6 months, and each vial should be thawed and used for only 24 hours. A prospective randomized human study showed that containers equipped with a sterilizing filter can be used for up to 4 weeks without any increased risk of contamination [56]. The concentrations of growth factors in 20% ASE remained stable for up to 9 months when kept frozen at −20°C and up to 4 weeks when defrosted [57].

3.2. Allogeneic Serum Eye Drops (SE)

Allogeneic SE from healthy donors can be advantageous in patients with fear or difficulty of blood sampling or coexisting blood disorders including anemia [58]. Moreover, it can also be a therapeutic option for patients with graft-versus-host disease (GVHD) or (SS), in which a considerable amount of proinflammatory cytokines could be included in their autologous serum [59]. Allogeneic SE can be prepared using the same protocol of ASE [58]. Because allogeneic SE includes anti-A and anti-B antibodies, it can theoretically cause an immune reaction against ABO antigens expressed on corneal and conjunctival epithelium [58]. Therefore, preparation of allogenic SE from ABO-identical donors or blood type AB donors is recommended [60, 61]. Studies demonstrated the efficacy of allogenic SE in DED, PED, neurotrophic keratitis, GVHD, and exposure keratopathy [60, 62, 63], indicating its potential as a viable alternative to ASE [36].

3.3. Umbilical Cord Serum Eye Drops (UCSE)

UCSE samples can be prepared using umbilical cord blood collected during delivery [36]. Rigorous screening for blood-borne infections is mandatory prior to donation [36, 58]. UCSE can also be a therapeutic option for patients with blood disorders or systemic inflammatory diseases, in which ASE is contraindicated [58]. Although allogeneic serum does have the same advantage, UCS contains a higher level of growth factors, neurotrophic factors, and essential tear components compared to allogeneic serum [31, 33, 64]. Moreover, compared to allogeneic serum, a substantially larger amount of UCSE can be obtained with a single sampling from one donor and can be distributed to multiple patients [58]. As UCSE contains high levels of neurotrophic factors such as substance P (SP), insulin-like growth factor- (IGF-) 1, and nerve growth factor (NGF) [32, 33], as well as growth factors including EGF and TGF-β [64], it is conceivably helpful for corneal nerve regeneration and epithelial healing. Studies have revealed that UCSE accelerated the recovery of PED and neurotrophic keratitis recalcitrant to conventional treatment [32, 33]. UCSE was shown to be more effective than ASE for the improvement of symptoms and signs of DED, particularly in severe cases associated with GVHD and SS [64, 65]. UCSE was superior to artificial tear in treating recurrent corneal erosions and reducing its recurrence [34]. In ocular chemical burn, UCSE resulted in faster corneal epithelial healing and milder corneal opacity compared to ASE or artificial tears [35]. UCSE is also shown to decrease early corneal haze and improve ocular surface parameters after laser epithelial keratomileusis (LASEK) [66].

3.4. Platelet-Derived Plasma Preparations

Platelet-derived plasma preparations contain a large amount of growth factors and cytokines [36, 58] and have been successfully used in maxillofacial and orthopedic surgery as well as in regenerative medicine for the promotion of tissue healing [67]. Various preparations have been developed, such as plasma rich in growth factors (PRGF), platelet-rich plasma (PRP), and platelet lysate [58]. PRGF is obtained by the filtration of plasma supernatants after centrifugation of the whole blood [68]. PRP is a plasma with increased concentrations of platelets obtained with an additional centrifugation of the whole blood [69]. Platelet lysate is collected by inducing platelet lysis and release of growth factors including platelet-derived growth factor (PDGF) using PRP [70].

Kim et al. [71] demonstrated that PRP was superior to ASE in the treatment of PED. PRGF was also suggested to be useful for the healing of PED [72]. PRP was shown to be effective for the improvement of both symptoms and signs of DED [73]. Plasma lysate was suggested to be helpful for the treatment of DED associated with GVHD or SS [74, 75]. PRP was also superior to conventional treatment for the recovery of visual acuity and corneal transparency in patients with ocular chemical injury [76]. In addition, PRP is potentially available for a biomaterial for ocular surface reconstruction [77, 78].

4. Growth Factors for Corneal Diseases

4.1. Nerve Growth Factor (NGF)

NGF facilitates corneal epithelial healing, which is mediated by the cleavage of β4 integrin and the upregulation of matrix metalloproteinase-9 [79]. Topical administration of NGF was shown to be effective in neurotrophic keratitis refractory to conventional treatment [8082]. NGF is also expected to be effective for the treatment of diabetic keratopathy, as it could alleviate inflammation and apoptosis of corneal cells that can occur in diabetes mellitus [83].

Topical NGF was also shown to have a beneficial effect for postoperative corneal wound healing [80]. Cellini et al. [84] demonstrated that topical NGF was superior to artificial tear for corneal reconstruction after cataract. Animal experimental studies revealed that topical application of NGF accelerated restoration of corneal sensitivity and promoted cornea epithelial proliferation and nerve regeneration after laser in situ keratomileusis (LASIK) or photorefractive keratectomy (PRK) [8587].

4.2. Substance P (SP) and Insulin-Like Growth Factor- (IGF-) 1

A randomized prospective study revealed that topical SP and IGF-1 combination therapy was useful for the prevention of superficial punctate keratopathy after cataract surgery in diabetic patients [88]. SP was shown to promote an epithelial healing process in diabetic cornea and attenuate hyperosmotic stress-induced apoptosis of corneal epithelial cells through the neurokinin-1 receptor signaling pathway [89, 90]. IGF-1 also facilitated the regeneration of corneal surface ultrastructure and nerves after LASIK in rabbit eyes [91].

4.3. Vascular Endothelial Growth Factor (VEGF)

VEGF can facilitate the functional and anatomical recovery after peripheral nerve damage [92]. Guaiquil et al. [93] demonstrated that VEGF-B treatment selectively promoted nerve regeneration and restored sensory and trophic functions of injured corneal nerves, suggesting that it might have a therapeutic potential for peripheral corneal nerve injury [93].

An experimental study revealed that the expression of endogenous VEGF-B was attenuated in regenerated corneal epithelium in a diabetic mouse model, whereas supplementation of exogenous VEGF-B accelerated corneal nerve regeneration [94].

4.4. Other Grow Factors

An animal study showed that pigment epithelial-derived factor, in conjunction with docosahexaenoic acid, might be effective for the treatment of DED caused by corneal nerve damage and neurotrophic keratitis [95]. Topical administration of neuroprotectin D1 was also shown to attenuate inflammation and facilitate nerve regeneration after corneal damage in a rabbit model [96]. Ciliary neurotrophic factor was shown to be able to activate corneal epithelial stem/progenitor cells and promote the corneal nerve regeneration and epithelial recovery, suggesting its therapeutic potential for diabetic keratopathy and limbal stem cell deficiency [97]. A randomized clinical study demonstrated that basic fibroblast growth factor promoted corneal epithelial healing after PRK, indicating it could be a therapeutic option for delayed healing [98].

4.5. Regenerating Agent Eye Drops (RGTAs)

RGTA (OTR4120 Cacicol20®; Théa, Clermont-Ferrand, France) is a carboxymethyl dextran sulfate polymer bioengineered to replace heparan sulfate, which is an important factor both for matrix proteins and for growth factors [99, 100]. Thus, RGTA is conceivably helpful for restoring equilibrium in cellular microenvironment [99, 101]. It is also expected to be useful for corneal wound healing, and several studies have shown promising results [99107].

Experimental studies using a rabbit corneal burn model and a clinical case series study suggested that RGTA might be an innovative agent for promoting corneal regeneration and attenuating ocular surface inflammation by reducing oxidative, proteolytic, and nitrosative corneal damage [104, 108, 109]. A clinical pilot study also revealed the efficacy of RGTA for corneal ulcers and dystrophies refractory to conventional treatment [105]. A prospective clinical study demonstrated that RGTA might be effective and safe for the treatment of neurotrophic keratitis [106]. Chappelet et al. [101] recently showed that RGTA could be useful for the treatment of a PED after bacterial keratitis [101].

RGTA ophthalmic solution was also reported to facilitate corneal epithelial healing after corneal cross-linking (CXL) by reconstruction of the extracellular matrix in the corneal wound area [99, 100]. A randomized clinical trial demonstrated that RGTA might be superior to topical hyaluronic acid for corneal wound recovery after CXL in patients with keratoconus [103].

In animal excimer laser models, topical RGTA reduced corneal haze and promoted nerve regeneration, suggesting that it could be a useful option for the restoration of corneal microarchitecture after keratorefractive surgery [102, 107].

5. Conclusion

In this review paper, we have introduced a number of research papers that have demonstrated the efficacy of pharmacologic therapies, such as ROCK inhibitors, blood-derived products, growth factors, and RGTA on corneal cell regeneration. The promising results of these studies suggest that these agents can be viable options to aid corneal cell regeneration.

In summary, the ROCK inhibitor can promote the regeneration of CECs and its adhesion to Descemet’s membrane. Thus, it can be used as a topical eye drops for the treatment of corneal endothelial dysfunction. It can also be used as an adjuvant therapy for CEC injection to AC. Blood-derived products can promote healing of ocular surface epithelium. Hence, it can be used for PED or neurotrophic keratitis. It can also be used for promoting ocular surface reconstruction and prevention of corneal opacity after ocular chemical injury. Growth factors promote the recovery of cornea epithelium and nerve; thus, these drugs can especially be helpful for PED, neurotrophic keratitis, and diabetic keratopathy. As RGTA facilitates corneal regeneration and attenuates ocular surface inflammation, it can be indicated for corneal regeneration after corneal CXL. It can also be helpful for the treatment of PDE or neurotrophic keratitis. The recovery of corneal epithelium and nerve after keratorefractive surgery can be facilitated by blood-derived products, growth factors, and RGTA (Table 1).

Table 1: Effect and possible application of the novel drugs.

Although these therapeutic agents are innovative, further prospective randomized studies are needed for the verification of the efficacy and safety of the drugs [3]. Further studies are also required for the development of novel therapeutic agents for corneal cell regeneration.

Conflicts of Interest

None of the authors have a proprietary interest in the study or financial interests to disclose.

Acknowledgments

This study was supported by 2017 Research Grant from Kangwon National University.

References

  1. J. P. Whitcher, M. Srinivasan, and M. P. Upadhyay, “Corneal blindness: a global perspective,” Bulletin of the World Health Organization, vol. 79, no. 3, pp. 214–221, 2001. View at Google Scholar
  2. N. Okumura, Y. Sakamoto, K. Fujii et al., “Rho kinase inhibitor enables cell-based therapy for corneal endothelial dysfunction,” Scientific Reports, vol. 6, no. 1, article 26113, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Okumura, S. Kinoshita, and N. Koizumi, “Application of Rho kinase inhibitors for the treatment of corneal endothelial diseases,” Journal of Ophthalmology, vol. 2017, Article ID 2646904, 8 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Nourinia, S. Nakao, S. Zandi, S. Safi, A. Hafezi-Moghadam, and H. Ahmadieh, “ROCK inhibitors for the treatment of ocular diseases,” British Journal of Ophthalmology, vol. 102, no. 1, 2017. View at Publisher · View at Google Scholar
  5. N. Koizumi, N. Okumura, M. Ueno, and S. Kinoshita, “New therapeutic modality for corneal endothelial disease using Rho-associated kinase inhibitor eye drops,” Cornea, vol. 33, Supplement 11, pp. S25–S31, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Okumura, N. Koizumi, M. Ueno et al., “Enhancement of corneal endothelium wound healing by Rho-associated kinase (ROCK) inhibitor eye drops,” British Journal of Ophthalmology, vol. 95, no. 7, pp. 1006–1009, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Okumura, S. Nakano, E. D. P. Kay et al., “Involvement of cyclin D and p27 in cell proliferation mediated by ROCK inhibitors Y-27632 and Y-39983 during corneal endothelium wound healing,” Investigative Ophthalmology & Visual Science, vol. 55, no. 1, pp. 318–329, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. G. S. L. Peh, K. Adnan, B. L. George et al., “The effects of Rho-associated kinase inhibitor Y-27632 on primary human corneal endothelial cells propagated using a dual media approach,” Scientific Reports, vol. 5, no. 1, p. 9167, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Pipparelli, Y. Arsenijevic, G. Thuret, P. Gain, M. Nicolas, and F. Majo, “ROCK inhibitor enhances adhesion and wound healing of human corneal endothelial cells,” PLoS One, vol. 8, no. 4, article e62095, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Okumura, N. Koizumi, M. Ueno et al., “The new therapeutic concept of using a rho kinase inhibitor for the treatment of corneal endothelial dysfunction,” Cornea, vol. 30, Supplement 1, pp. S54–S59, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Okumura, N. Koizumi, E. D. P. Kay et al., “The ROCK inhibitor eye drop accelerates corneal endothelium wound healing,” Investigative Ophthalmology & Visual Science, vol. 54, no. 4, pp. 2493–2502, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Okumura, M. Ueno, N. Koizumi et al., “Enhancement on primate corneal endothelial cell survival in vitro by a ROCK inhibitor,” Investigative Ophthalmology & Visual Science, vol. 50, no. 8, pp. 3680–3687, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Okumura, S. Kinoshita, and N. Koizumi, “The role of rho kinase inhibitors in corneal endothelial dysfunction,” Current Pharmaceutical Design, vol. 23, no. 4, pp. 660–666, 2017. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Koizumi, N. Okumura, M. Ueno, H. Nakagawa, J. Hamuro, and S. Kinoshita, “Rho-associated kinase inhibitor eye drop treatment as a possible medical treatment for Fuchs corneal dystrophy,” Cornea, vol. 32, no. 8, pp. 1167–1170, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Moloney, C. Petsoglou, M. Ball et al., “Descemetorhexis without grafting for Fuchs endothelial dystrophy-supplementation with topical ripasudil,” Cornea, vol. 36, no. 6, pp. 642–648, 2017. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Koizumi, Y. Sakamoto, N. Okumura et al., “Cultivated corneal endothelial cell sheet transplantation in a primate model,” Investigative Ophthalmology & Visual Science, vol. 48, no. 10, pp. 4519–4526, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Mimura, S. Yamagami, S. Yokoo et al., “Cultured human corneal endothelial cell transplantation with a collagen sheet in a rabbit model,” Investigative Ophthalmology & Visual Science, vol. 45, no. 9, pp. 2992–2997, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Mimura, N. Shimomura, T. Usui et al., “Magnetic attraction of iron-endocytosed corneal endothelial cells to Descemet’s membrane,” Experimental Eye Research, vol. 76, no. 6, pp. 745–751, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Mimura, S. Yamagami, T. Usui et al., “Long-term outcome of iron-endocytosing cultured corneal endothelial cell transplantation with magnetic attraction,” Experimental Eye Research, vol. 80, no. 2, pp. 149–157, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. I. H. Ma, L. W. Chen, W. H. Tu, C. J. Lu, C. J. Huang, and W. L. Chen, “Serum components and clinical efficacies of autologous serum eye drops in dry eye patients with active and inactive Sjogren syndrome,” Taiwan Journal of Ophthalmology, vol. 7, no. 4, pp. 213–220, 2017. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Mimura, S. Yamagami, S. Yokoo et al., “Sphere therapy for corneal endothelium deficiency in a rabbit model,” Investigative Ophthalmology & Visual Science, vol. 46, no. 9, pp. 3128–3135, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Okumura, N. Koizumi, M. Ueno et al., “ROCK inhibitor converts corneal endothelial cells into a phenotype capable of regenerating in vivo endothelial tissue,” The American Journal of Pathology, vol. 181, no. 1, pp. 268–277, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. C. C. Sun, H. T. Chiu, Y. F. Lin, K. Y. Lee, and J. H. S. Pang, “Y-27632, a ROCK inhibitor, promoted limbal epithelial cell proliferation and corneal wound healing,” PLoS One, vol. 10, no. 12, article e0144571, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. Q. Zhou, H. Duan, Y. Wang, M. Qu, L. Yang, and L. Xie, “ROCK inhibitor Y-27632 increases the cloning efficiency of limbal stem/progenitor cells by improving their adherence and ROS-scavenging capacity,” Tissue Engineering. Part C: Methods, vol. 19, no. 7, pp. 531–537, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Yamamoto, A. J. Quantock, R. D. Young et al., “A selective inhibitor of the Rho kinase pathway, Y-27632, and its influence on wound healing in the corneal stroma,” Molecular Vision, vol. 18, pp. 1727–1739, 2012. View at Google Scholar
  26. P. Zeng, R. B. Pi, P. Li et al., “Fasudil hydrochloride, a potent ROCK inhibitor, inhibits corneal neovascularization after alkali burns in mice,” Molecular Vision, vol. 21, pp. 688–698, 2015. View at Google Scholar
  27. D. Sijnave, T. Van Bergen, K. Castermans et al., “Inhibition of Rho-associated kinase prevents pathological wound healing and neovascularization after corneal trauma,” Cornea, vol. 34, no. 9, pp. 1120–1129, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. R. A. Ralph, M. G. Doane, and C. H. Dohlman, “Clinical experience with a mobile ocular perfusion pump,” Archives of Ophthalmology, vol. 93, no. 10, pp. 1039–1043, 1975. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Tsubota, E. Goto, S. Shimmura, and J. Shimazaki, “Treatment of persistent corneal epithelial defect by autologous serum application,” Ophthalmology, vol. 106, no. 10, pp. 1984–1989, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Tsubota, E. Goto, H. Fujita et al., “Treatment of dry eye by autologous serum application in Sjogren’s syndrome,” British Journal of Ophthalmology, vol. 83, no. 4, pp. 390–395, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. K. C. Yoon, S. K. Im, Y. G. Park, Y. D. Jung, S. Y. Yang, and J. Choi, “Application of umbilical cord serum eyedrops for the treatment of dry eye syndrome,” Cornea, vol. 25, no. 3, pp. 268–272, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. K. C. Yoon, H. Heo, I. Y. Jeong, and Y. G. Park, “Therapeutic effect of umbilical cord serum eyedrops for persistent corneal epithelial defect,” Korean Journal of Ophthalmology, vol. 19, no. 3, pp. 174–178, 2005. View at Publisher · View at Google Scholar
  33. K. C. Yoon, I. C. You, S. K. Im, T. S. Jeong, Y. G. Park, and J. Choi, “Application of umbilical cord serum eyedrops for the treatment of neurotrophic keratitis,” Ophthalmology, vol. 114, no. 9, pp. 1637–1642.e2, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. K. C. Yoon, W. Choi, I. C. You, and J. Choi, “Application of umbilical cord serum eyedrops for recurrent corneal erosions,” Cornea, vol. 30, no. 7, pp. 744–748, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. N. Sharma, M. Goel, T. Velpandian, J. S. Titiyal, R. Tandon, and R. B. Vajpayee, “Evaluation of umbilical cord serum therapy in acute ocular chemical burns,” Investigative Ophthalmology & Visual Science, vol. 52, no. 2, pp. 1087–1092, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. N. G. Soni and B. H. Jeng, “Blood-derived topical therapy for ocular surface diseases,” British Journal of Ophthalmology, vol. 100, no. 1, pp. 22–27, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. G. Geerling, S. Maclennan, and D. Hartwig, “Autologous serum eye drops for ocular surface disorders,” British Journal of Ophthalmology, vol. 88, no. 11, pp. 1467–1474, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. C. Yamada, K. E. King, and P. M. Ness, “Autologous serum eyedrops: literature review and implications for transfusion medicine specialists,” Transfusion, vol. 48, no. 6, pp. 1245–1255, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. L. Liu, D. Hartwig, S. Harloff, P. Herminghaus, T. Wedel, and G. Geerling, “An optimised protocol for the production of autologous serum eyedrops,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 243, no. 7, pp. 706–714, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. B. H. Jeng and W. J. Dupps Jr, “Autologous serum 50% eyedrops in the treatment of persistent corneal epithelial defects,” Cornea, vol. 28, no. 10, pp. 1104–1108, 2009. View at Publisher · View at Google Scholar
  41. K. Lekhanont, P. Jongkhajornpong, L. Choubtum, and V. Chuckpaiwong, “Topical 100% serum eye drops for treating corneal epithelial defect after ocular surgery,” BioMed Research International, vol. 2013, Article ID 521315, 7 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. K. Cho, W. Huang, G. Y. Kim, and B. S. Lim, “Comparison of autologous serum eye drops with different diluents,” Current Eye Research, vol. 38, no. 1, pp. 9–17, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. B. A. Noble, R. S. Loh, S. MacLennan et al., “Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease,” British Journal of Ophthalmology, vol. 88, no. 5, pp. 647–652, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. T. Kojima, R. Ishida, M. Dogru et al., “The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study,” American Journal of Ophthalmology, vol. 139, no. 2, pp. 242–246, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. A. R. C. Celebi, C. Ulusoy, and G. E. Mirza, “The efficacy of autologous serum eye drops for severe dry eye syndrome: a randomized double-blind crossover study,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 252, no. 4, pp. 619–626, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Kojima, A. Higuchi, E. Goto, Y. Matsumoto, M. Dogru, and K. Tsubota, “Autologous serum eye drops for the treatment of dry eye diseases,” Cornea, vol. 27, Supplement 1, pp. S25–S30, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Noda-Tsuruya, N. Asano-Kato, I. Toda, and K. Tsubota, “Autologous serum eye drops for dry eye after LASIK,” Journal of Refractive Surgery, vol. 22, no. 1, pp. 61–66, 2006. View at Google Scholar
  48. A. C. Poon, G. Geerling, J. K. Dart, G. E. Fraenkel, and J. T. Daniels, “Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies,” British Journal of Ophthalmology, vol. 85, no. 10, pp. 1188–1197, 2001. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Schrader, T. Wedel, R. Moll, and G. Geerling, “Combination of serum eye drops with hydrogel bandage contact lenses in the treatment of persistent epithelial defects,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 244, no. 10, pp. 1345–1349, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. Y. M. Chen, F. R. Hu, J. Y. Huang, E. P. Shen, T. Y. Tsai, and W. L. Chen, “The effect of topical autologous serum on graft re-epithelialization after penetrating keratoplasty,” American Journal of Ophthalmology, vol. 150, no. 3, pp. 352–359.e2, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. Matsumoto, M. Dogru, E. Goto et al., “Autologous serum application in the treatment of neurotrophic keratopathy,” Ophthalmology, vol. 111, no. 6, pp. 1115–1120, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. J. S. Lopez-Garcia, L. Rivas, I. Garcia-Lozano, and J. Murube, “Autologous serum eyedrops in the treatment of aniridic keratopathy,” Ophthalmology, vol. 115, no. 2, pp. 262–267, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. N. G. Ziakas, K. G. Boboridis, C. Terzidou et al., “Long-term follow up of autologous serum treatment for recurrent corneal erosions,” Clinical & Experimental Ophthalmology, vol. 38, no. 7, pp. 683–687, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. Q. Pan, A. Angelina, M. Marrone et al., “Autologous serum eye drops for dry eye,” Cochrane Database of Systematic Reviews, vol. 2, article CD009327, 2017. View at Publisher · View at Google Scholar
  55. R. Lagnado, A. J. King, F. Donald, and H. S. Dua, “A protocol for low contamination risk of autologous serum drops in the management of ocular surface disorders,” British Journal of Ophthalmology, vol. 88, no. 4, pp. 464-465, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. J. S. Lopez-Garcia and I. Garcia-Lozano, “Use of containers with sterilizing filter in autologous serum eyedrops,” Ophthalmology, vol. 119, no. 11, pp. 2225–2230, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. J. S. Lopez-Garcia, I. Garcia-Lozano, L. Rivas, N. Ramírez, M. T. Méndez, and R. Raposo, “Stability of growth factors in autologous serum eyedrops after long-term storage,” Current Eye Research, vol. 41, no. 3, pp. 1–7, 2016. View at Publisher · View at Google Scholar · View at Scopus
  58. G. Giannaccare, P. Versura, M. Buzzi, L. Primavera, M. Pellegrini, and E. C. Campos, “Blood derived eye drops for the treatment of cornea and ocular surface diseases,” Transfusion and Apheresis Science, vol. 56, no. 4, pp. 595–604, 2017. View at Publisher · View at Google Scholar · View at Scopus
  59. P. A. Stenwall, M. Bergstrom, P. Seiron et al., “Improving the anti-inflammatory effect of serum eye drops using allogeneic serum permissive for regulatory T cell induction,” Acta Ophthalmologica, vol. 93, no. 7, pp. 654–657, 2015. View at Publisher · View at Google Scholar · View at Scopus
  60. L. H. Harritshoj, C. Nielsen, H. Ullum, M. B. Hansen, and H. O. Julian, “Ready-made allogeneic ABO-specific serum eye drops: production from regular male blood donors, clinical routine, safety and efficacy,” Acta Ophthalmologica, vol. 92, no. 8, pp. 783–786, 2014. View at Publisher · View at Google Scholar · View at Scopus
  61. K. G. Badami and M. McKellar, “Allogeneic serum eye drops: time these became the norm?” British Journal of Ophthalmology, vol. 96, no. 8, pp. 1151-1152, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. C. C. Chiang, W. L. Chen, J. M. Lin, and Y. Y. Tsai, “Allogeneic serum eye drops for the treatment of persistent corneal epithelial defect,” Eye, vol. 23, no. 2, pp. 290–293, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. K. S. Na and M. S. Kim, “Allogeneic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease,” Journal of Ocular Pharmacology and Therapeutics, vol. 28, no. 5, pp. 479–483, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. K. C. Yoon, H. Heo, S. K. Im, I. C. You, Y. H. Kim, and Y. G. Park, “Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome,” American Journal of Ophthalmology, vol. 144, no. 1, pp. 86–92.e2, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. K. C. Yoon, I. Y. Jeong, S. K. Im, Y. G. Park, H. J. Kim, and J. Choi, “Therapeutic effect of umbilical cord serum eyedrops for the treatment of dry eye associated with graft-versus-host disease,” Bone Marrow Transplantation, vol. 39, no. 4, pp. 231–235, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. K. C. Yoon, H. J. Oh, J. W. Park, and J. Choi, “Application of umbilical cord serum eyedrops after laser epithelial keratomileusis,” Acta Ophthalmologica, vol. 91, no. 1, pp. e22–e28, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. B. H. Choi, C. J. Im, J. Y. Huh, J. J. Suh, and S. H. Lee, “Effect of platelet-rich plasma on bone regeneration in autogenous bone graft,” International Journal of Oral and Maxillofacial Surgery, vol. 33, no. 1, pp. 56–59, 2004. View at Publisher · View at Google Scholar · View at Scopus
  68. E. Anitua, M. de la Fuente, F. Muruzabal, A. Riestra, J. Merayo-Lloves, and G. Orive, “Plasma rich in growth factors (PRGF) eye drops stimulates scarless regeneration compared to autologous serum in the ocular surface stromal fibroblasts,” Experimental Eye Research, vol. 135, pp. 118–126, 2015. View at Publisher · View at Google Scholar · View at Scopus
  69. S. T. Tanidir, N. Yuksel, O. Altintas, D. K. Yildiz, E. Sener, and Y. Caglar, “The effect of subconjunctival platelet-rich plasma on corneal epithelial wound healing,” Cornea, vol. 29, no. 6, pp. 664–669, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. L. Liu, D. Hartwig, S. Harloff et al., “Corneal epitheliotrophic capacity of three different blood-derived preparations,” Investigative Ophthalmology & Visual Science, vol. 47, no. 6, pp. 2438–2444, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. K. M. Kim, Y. T. Shin, and H. K. Kim, “Effect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis,” Japanese Journal of Ophthalmology, vol. 56, no. 6, pp. 544–550, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Lopez-Plandolit, M. C. Morales, V. Freire, J. Etxebarría, and J. A. Durán, “Plasma rich in growth factors as a therapeutic agent for persistent corneal epithelial defects,” Cornea, vol. 29, no. 8, pp. 843–848, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. J. L. Alio, A. E. Rodriguez, R. Ferreira-Oliveira, D. Wróbel-Dudzińska, and A. A. Abdelghany, “Treatment of dry eye disease with autologous platelet-rich plasma: a prospective, interventional, non-randomized study,” Ophthalmology and Therapy, vol. 6, no. 2, pp. 285–293, 2017. View at Publisher · View at Google Scholar
  74. S. Pezzotta, C. Del Fante, L. Scudeller, M. Cervio, E. R. Antoniazzi, and C. Perotti, “Autologous platelet lysate for treatment of refractory ocular GVHD,” Bone Marrow Transplantation, vol. 47, no. 12, pp. 1558–1563, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. A. M. Fea, V. Aragno, V. Testa et al., “The effect of autologous platelet lysate eye drops: an in vivo confocal microscopy study,” BioMed Research International, vol. 2016, Article ID 8406832, 10 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  76. A. Panda, M. Jain, M. Vanathi, T. Velpandian, S. Khokhar, and T. Dada, “Topical autologous platelet-rich plasma eyedrops for acute corneal chemical injury,” Cornea, vol. 31, no. 9, pp. 989–993, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. J. L. Alio, A. E. Rodriguez, and L. M. Martinez, “Bovine pericardium membrane (tutopatch) combined with solid platelet-rich plasma for the management of perforated corneal ulcers,” Cornea, vol. 32, no. 5, pp. 619–624, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. J. L. Alio, A. E. Rodriguez, L. M. Martinez, and A. L. Rio, “Autologous fibrin membrane combined with solid platelet-rich plasma in the management of perforated corneal ulcers: a pilot study,” JAMA Ophthalmology, vol. 131, no. 6, pp. 745–751, 2013. View at Publisher · View at Google Scholar · View at Scopus
  79. T. Blanco-Mezquita, C. Martinez-Garcia, R. Proenca et al., “Nerve growth factor promotes corneal epithelial migration by enhancing expression of matrix metalloprotease-9,” Investigative Ophthalmology & Visual Science, vol. 54, no. 6, pp. 3880–3890, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. A. Lambiase, M. Sacchetti, and S. Bonini, “Nerve growth factor therapy for corneal disease,” Current Opinion in Ophthalmology, vol. 23, no. 4, pp. 296–302, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. F. R. Ghosheh, F. Cremona, B. D. Ayres et al., “Indications for penetrating keratoplasty and associated procedures, 2001-2005,” Eye & Contact Lens, vol. 34, no. 4, pp. 211–214, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. S. Bonini, A. Lambiase, P. Rama, G. Caprioglio, and L. Aloe, “Topical treatment with nerve growth factor for neurotrophic keratitis,” Ophthalmology, vol. 107, no. 7, pp. 1347–1351, 2000. View at Publisher · View at Google Scholar · View at Scopus
  83. J. H. Park, S. S. Kang, J. Y. Kim, and H. Tchah, “Nerve growth factor attenuates apoptosis and inflammation in the diabetic cornea,” Investigative Ophthalmology & Visual Science, vol. 57, no. 15, pp. 6767–6775, 2016. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Cellini, E. Bendo, G. O. Bravetti, and E. C. Campos, “The use of nerve growth factor in surgical wound healing of the cornea,” Ophthalmic Research, vol. 38, no. 4, pp. 177–181, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. M. J. Joo, K. R. Yuhan, J. Y. Hyon et al., “The effect of nerve growth factor on corneal sensitivity after laser in situ keratomileusis,” Archives of Ophthalmology, vol. 122, no. 9, pp. 1338–1341, 2004. View at Publisher · View at Google Scholar · View at Scopus
  86. S. Esquenazi, H. E. P. Bazan, V. Bui, J. He, D. B. Kim, and N. G. Bazan, “Topical combination of NGF and DHA increases rabbit corneal nerve regeneration after photorefractive keratectomy,” Investigative Ophthalmology & Visual Science, vol. 46, no. 9, pp. 3121–3127, 2005. View at Publisher · View at Google Scholar · View at Scopus
  87. K. Ma, N. Yan, Y. Huang, G. Cao, J. Deng, and Y. Deng, “Effects of nerve growth factor on nerve regeneration after corneal nerve damage,” International Journal of Clinical and Experimental Medicine, vol. 7, no. 11, pp. 4584–4589, 2014. View at Google Scholar
  88. N. Chikamoto, T. Chikama, N. Yamada, T. Nishida, T. Ishimitsu, and A. Kamiya, “Efficacy of substance P and insulin-like growth factor-1 peptides for preventing postsurgical superficial punctate keratopathy in diabetic patients,” Japanese Journal of Ophthalmology, vol. 53, no. 5, pp. 464–469, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. L. Yang, G. Di, X. Qi et al., “Substance P promotes diabetic corneal epithelial wound healing through molecular mechanisms mediated via the neurokinin-1 receptor,” Diabetes, vol. 63, no. 12, pp. 4262–4274, 2014. View at Publisher · View at Google Scholar · View at Scopus
  90. L. Yang, W. Sui, Y. Li et al., “Substance P inhibits hyperosmotic stress-induced apoptosis in corneal epithelial cells through the mechanism of Akt activation and reactive oxygen species scavenging via the neurokinin-1 receptor,” PLoS One, vol. 11, no. 2, article e0149865, 2016. View at Publisher · View at Google Scholar · View at Scopus
  91. C. Wang, Y. Peng, S. Pan, and L. Li, “Effect of insulin-like growth factor-1 on corneal surface ultrastructure and nerve regeneration of rabbit eyes after laser in situ keratomileusis,” Neuroscience Letters, vol. 558, pp. 169–174, 2014. View at Publisher · View at Google Scholar · View at Scopus
  92. Z. Pan, S. Fukuoka, N. Karagianni, V. H. Guaiquil, and M. I. Rosenblatt, “Vascular endothelial growth factor promotes anatomical and functional recovery of injured peripheral nerves in the avascular cornea,” The FASEB Journal, vol. 27, no. 7, pp. 2756–2767, 2013. View at Publisher · View at Google Scholar · View at Scopus
  93. V. H. Guaiquil, Z. Pan, N. Karagianni, S. Fukuoka, G. Alegre, and M. I. Rosenblatt, “VEGF-B selectively regenerates injured peripheral neurons and restores sensory and trophic functions,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 48, pp. 17272–17277, 2014. View at Publisher · View at Google Scholar · View at Scopus
  94. G. Di, X. Zhao, X. Qi et al., “VEGF-B promotes recovery of corneal innervations and trophic functions in diabetic mice,” Scientific Reports, vol. 7, article 40582, 2017. View at Publisher · View at Google Scholar · View at Scopus
  95. J. He, M. S. Cortina, A. Kakazu, and H. E. P. Bazan, “The PEDF neuroprotective domain plus DHA induces corneal nerve regeneration after experimental surgery,” Investigative Ophthalmology & Visual Science, vol. 56, no. 6, pp. 3505–3513, 2015. View at Publisher · View at Google Scholar · View at Scopus
  96. M. S. Cortina, J. He, T. Russ, N. G. Bazan, and H. E. P. Bazan, “Neuroprotectin D1 restores corneal nerve integrity and function after damage from experimental surgery,” Investigative Ophthalmology & Visual Science, vol. 54, no. 6, pp. 4109–4116, 2013. View at Publisher · View at Google Scholar · View at Scopus
  97. Q. Zhou, P. Chen, G. Di et al., “Ciliary neurotrophic factor promotes the activation of corneal epithelial stem/progenitor cells and accelerates corneal epithelial wound healing,” Stem Cells, vol. 33, no. 5, pp. 1566–1576, 2015. View at Publisher · View at Google Scholar · View at Scopus
  98. A. Meduri, P. Aragona, P. L. Grenga, and A. M. Roszkowska, “Effect of basic fibroblast growth factor on corneal epithelial healing after photorefractive keratectomy,” Journal of Refractive Surgery, vol. 28, no. 3, pp. 220–223, 2012. View at Publisher · View at Google Scholar · View at Scopus
  99. K. Gumus, M. G. Guerra, S. H. de Melo Marques, S. Karaküçük, and D. Barritault, “A new matrix therapy agent for faster corneal healing and less ocular discomfort following epi-off accelerated corneal cross-linking in progressive keratoconus,” Journal of Refractive Surgery, vol. 33, no. 3, pp. 163–170, 2017. View at Publisher · View at Google Scholar · View at Scopus
  100. G. D. Kymionis, D. A. Liakopoulos, M. A. Grentzelos et al., “Effect of the regenerative agent poly(carboxymethylglucose sulfate) on corneal wound healing after corneal cross-linking for keratoconus,” Cornea, vol. 34, no. 8, pp. 928–931, 2015. View at Publisher · View at Google Scholar · View at Scopus
  101. M. A. Chappelet, D. Bernheim, C. Chiquet, and F. Aptel, “Effect of a new matrix therapy agent in persistent epithelial defects after bacterial keratitis treated with topical fortified antibiotics,” Cornea, vol. 36, no. 9, pp. 1061–1068, 2017. View at Publisher · View at Google Scholar · View at Scopus
  102. I. Alcalde, A. Inigo-Portugues, N. Carreño, A. C. Riestra, and J. M. Merayo-Lloves, “Effects of new biomimetic regenerating agents on corneal wound healing in an experimental model of post-surgical corneal ulcers,” Archivos de la Sociedad Española de Oftalmología, vol. 90, no. 10, pp. 467–474, 2015. View at Publisher · View at Google Scholar · View at Scopus
  103. A. M. Bata, K. J. Witkowska, P. A. Wozniak et al., “Effect of a matrix therapy agent on corneal epithelial healing after standard collagen cross-linking in patients with keratoconus: a randomized clinical trial,” JAMA Ophthalmology, vol. 134, no. 10, pp. 1169–1176, 2016. View at Publisher · View at Google Scholar · View at Scopus
  104. F. Brignole-Baudouin, J. M. Warnet, D. Barritault, and C. Baudouin, “RGTA-based matrix therapy in severe experimental corneal lesions: safety and efficacy studies,” Journal Français d'Ophtalmologie, vol. 36, no. 9, pp. 740–747, 2013. View at Publisher · View at Google Scholar · View at Scopus
  105. C. K. Chebbi, K. Kichenin, N. Amar et al., “Pilot study of a new matrix therapy agent (RGTA OTR4120) in treatment-resistant corneal ulcers and corneal dystrophy,” Journal Français d'Ophtalmologie, vol. 31, no. 5, pp. 465–471, 2008. View at Google Scholar
  106. M. Guerra, S. Marques, J. Q. Gil et al., “Neurotrophic keratopathy: therapeutic approach using a novel matrix regenerating agent,” Journal of Ocular Pharmacology and Therapeutics, vol. 33, no. 9, pp. 662–669, 2017. View at Publisher · View at Google Scholar · View at Scopus
  107. M. Xeroudaki, B. Peebo, J. Germundsson, P. Fagerholm, and N. Lagali, “RGTA in corneal wound healing after transepithelial laser ablation in a rabbit model: a randomized, blinded, placebo-controlled study,” Acta Ophthalmologica, vol. 94, no. 7, pp. 685–691, 2016. View at Publisher · View at Google Scholar · View at Scopus
  108. R. P. J. Arvola, A. Robciuc, and J. M. Holopainen, “Matrix regeneration therapy: a case series of corneal neurotrophic ulcers,” Cornea, vol. 35, no. 4, pp. 451–455, 2016. View at Publisher · View at Google Scholar · View at Scopus
  109. J. Cejkova, C. Olmiere, C. Cejka, P. Trosan, and V. Holan, “The healing of alkali-injured cornea is stimulated by a novel matrix regenerating agent (RGTA, CACICOL20): a biopolymer mimicking heparan sulfates reducing proteolytic, oxidative and nitrosative damage,” Histology and Histopathology, vol. 29, no. 4, pp. 457–478, 2014. View at Publisher · View at Google Scholar